EcoDrugPlus

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSCHAG00000009426
Gene Symbol: MAPK11
1 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 14b

Ensembl ID : ENSCHAG00000020731
Gene Symbol: MAPK14B
1 Cross references
186 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSCHAG00000012127
Gene Symbol: MAPK3
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSCHAG00000009439
Gene Symbol: LOC105904364
3 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSCHAG00000001292
Gene Symbol: MAPK8B
1 Cross references
223 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSCHAG00000011997
Gene Symbol: MAPK9
3 Cross references
170 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSCHAG00000000220
Gene Symbol: MAP2K1
1 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSCHAG00000023747
Gene Symbol: MAP2K1
1 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSCHAG00000016808
Gene Symbol: MAP3K10
3 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSCHAG00000013834
Gene Symbol: MAP3K11
1 Cross references
181 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSCHAG00000027879
Gene Symbol: MAP3K12
1 Cross references
184 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSCHAG00000025697
Gene Symbol: MAP3K13
1 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).